Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abelacimab vs. Dalteparin in GI/GU Associated VTE
NCT05171075Phase 3Terminated
- Sponsor
- Anthos Therapeutics
- Start
- Sep 2022
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial of abelacimab in venous thromboembolism (VTE) (2 arms), sponsored by Anthos Therapeutics. Primary endpoint: Time to first event of centrally adjudicated VTE recurrence at 6 months. Started Sep 2022; status: terminated.
02
Drugs
abelacimab
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT05171075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05171075.